Clinical implications of blast immunophenotypes in myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 46, Issue 9, 2005, Pages 1269-1274

  Ogata, Kiyoyuki ^a   Yoshida, Yataro ^b  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TAKEDA GENERAL HOSPITAL   (Japan)

Author keywords

Blasts; CD7; Immunophenotypes; Myelodysplastic syndromes

Indexed keywords

CD19 ANTIGEN; CD2 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; REAGENT;

ACUTE LEUKEMIA; ANTIGEN EXPRESSION; BLAST CELL; CANCER SURVIVAL; CLINICAL PRACTICE; CYTOCHEMISTRY; DENSITY GRADIENT CENTRIFUGATION; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; IMMUNOPHENOTYPING; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANTIGENS, CD; ANTIGENS, CD34; DISEASE PROGRESSION; HUMANS; IMMUNOPHENOTYPING; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 24644517584     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500142155     Document Type: Review

References (45)

1. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 1993;7:144-146.
2. Yoshida Y, Stephenson J, Mufti GJ. Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. Int J Hematol 1993;57:87-97.
3. Kerndrup G, Bendix-Hansen K, Pedersen B, Ellegaard J, Hokland P. Analysis of leucocyte differentiation antigens in blood and bone marrow in patients with refractory anaemia (RA) and RA with sideroblasts. Prognostic implications of sequential and follow-up data. Eur J Haematol 1988;41:368-374.
4. Symeonidis A, Kourakli A, Katevas P, Perraki M, Tiniakou M, Matsouka P, Georgoulias V, Zoumbos N. Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur J Haematol 1991;47:277-281.
5. Colombat PH, Renoux M, Lamagnere JP, Renoux G. Immunologic indices in myelodysplastic syndromes. Cancer 1988;61:1075-1081.
6. Mittelman M, Karcher DS, Kammerman LA, Lessin LS. High Ia (HLA-DR) and low CD11b (Mo1) expression may predict early conversion to leukemia in myelodysplastic syndromes. Am J Hematol 1993;43:165-171.
7. Hokland P, Kerndrup G, Griffin JD, Ellegaard J. Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood 1986;67:898-902.
8. Kristensen JS, Hokland P. Monoclonal antibody ratios in malignant myeloid diseases: diagnostic and prognostic use in myelodysplastic syndromes. Br J Haematol 1990;74:270-276.
9. Guyotat D, Campos L, Thomas X, Vila L, Shi ZH, Charrin C, Gentilhomme O, Fiere D. Myelodysplastic syndromes: a study of surface markers and in vitro growth patterns. Am J Hematol 1990;34:26-31.
10. Soligo DA, Oriani A, Annaloro C, Cortelezzi A, Calori R, Pozzoli E, Nosella D, Orazi A, Deliliers GL. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes. Am J Hematol 1994;46: 9-17.
11. Oriani A, Annaloro C, Soligo D, Pozzoli E, Cortelezzi A, Lambertenghi Deliliers G. Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes. Br J Haematol 1996;92:360-364.
12. Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Haematological 1998;83:1104-1115.
13. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001;98:979-987.
14. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, Deeg HJ. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102: 394-403.
15. Kussick SJ, Wood BL. Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med 2003;127:1140-1147.
16. Maynadié M, Picard F, Husson B, Chatelain B, Cornet Y, Le Roux G, Campos L, Dromelet A, Lepelley P, Jouault H, et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002;100:2349-2356.
17. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
18. Oertel J, Oertel B, Beyer J, Huhn D. CD 34 immunotyping of blasts in myelodysplasia Ann Hematol 1994;68:77-80.
19. Baur AS, Meugé-Moraw C, Schmidt PM, Parlier V, Jotterand M, Delacrétaz F. CD34/QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes. Eur J Haematol 2000;64:71-79.
20. Ramos F, Fernández-Ferrero S, Suárez D, Barbón M, Rodriguez JA, Gil S, Megido M, Ciudad J, Lopez N, del Canizo C, et al. Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk Res 1999;23:283-290.
21. Ogata K. Usefulness of a novel Blastretriever for harvesting blasts. Nippon Rinsho 2001;59:2353-2357.
22. Ogata K. Utility and validation studies on a novel method for harvesting blasts J. Jpn Soc Lab Hematol 2003;4:187-192.
23. Hyodo H, Ogata K, Tachibana M, Dan K. Characterization of blasts in clinical samples containing few blasts. Int J Hematol 2003;77:376-382.
24. Zipursky A, Bow E, Seshadri RS and Brown, EJ. Leukocyte density and volume in normal subjects and in patients with acute lymphoblastic leukemia. Blood 1976;48:361-371.
25. -) in patients with myelodysplastic syndromes Stem Cells. 2005; 23:619-630.
26. Messner H, Till JE, McCulloch EA. Density distributions of marrow cells from mouse and man. Ser Haematol 1972;5:22-36.
27. Ogata K, Nakamura K, Yokose N, Tamura H, Tachibana M, Taniguchi O, Iwakiri R, Hayashi T, Sakamaki H, Murai Y, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002;100: 3887-3896.
28. Ogata K, Satoh C, Hyodo H, Tamura H, Dan K and Yoshida, Y. Association between phenotypic features of blasts and the blast percentage in bone marrow of patients with myelodysplastic syndromes. Leuk Res 2004;28:1171-1175.
29. Bradstock K, Matthews J, Benson E, Page F, Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group Blood 1994; 84:1220-1225.
30. Wang JC, Beauregard P, Soamboonsrup P, Neame PB. Monoclonal antibodies in the management of acute leukemia. Am J Hematol 1995;50:188-199.
31. Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox MC, Stasi R, Bruno A, Aronica G, Maffei L, Suppo G, et al. Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. Blood 1997;89:621-629.
32. Khalidi, HS Medeiros, LJ Chang, KL Brynes, RK Slovak, ML Arber, DA. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol 1998;109:211-220.
33. Cuneo A, Ferrant A, Michaux JL, Boogaerts M, Demuynck H, Van Orshoven A, Criel A, Stul M, Dal CP, Hernandez J. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. Blood 1995;85:3688-3694.
34. Loken MR, Wells DA. Normal antigen expression in hematopoiesis. Basis for interpreting leukemia phenotypes. In: Stewart CC, Nicholson JKA, editors. Immunophenotyping. New York: Wiley-Liss; 2000. pp 133-60.
35. Chabannon C, Wood P, Torok Storb B. (1992) Expression of CD7 on normal human myeloid progenitors J Immunol 149 2110-3.
36. Catlett JP, Leftwich JA, Westin EH, Grant S and Huff, TF. c-kit expression by CD34+ bone marrow progenitors and inhibition of response to recombinant human interleukin-3 following exposure to c-kit antisense oligonucleotides. Blood 1991;78:3186-3191.
37. Carrera AC, Rincon M, Sanchez Madrid F, Lopez Botet M, de Landazuri Mo. Triggering of co-mitogenic signals in T cell proliferation by anti-LFA-1 (CD18, CD11a), LFA-3, and CD7 monoclonal antibodies. J Immunol 1988;141:1919-1924.
38. Carrel S, Salvi S, Rafti F, Favrot M, Rapin C, Sekaly RP. Direct involvement of CD7 (gp40) in activation of TcR gamma/delta+ T cells. Eur J Immunol 1991;21:1195-1200.
39. Shimizu Y, van Seventer Ga, Ennis E, Newman W, Horgan KJ, Shaw S. Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T cell adhesion. J Exp Med 1992;175:577-582.
40. Hou Z, Leta E, Jung LK. Cross-linking CD7 on myeloblasts results in granulocyte-macrophage colony-stimulating factor production. Blood 1996;88:124-129.
41. Ogata K, Yokose N, Shioi Y, Ishida Y, Tomiyama J, Hamaguchi H, Yagasaki F, Bessyo M, Sakamaki H, Dan K, et al. Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. Br J Haematol 2001;115: 612-615.
42. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
43. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, Harris NL. Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp 61-73.
44. Hrusák O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002;16: 1233-1258.
45. Hurwitz CA, Raimondi SC, Head D, Krance R, Mirro J Jr, Kalwinsky DK, Ayers GD, Behm FG. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 1992;80:3182-3188.